Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Liminal BioSciences Inc. PFSCF


Primary Symbol: LMNL

Liminal BioSciences is a biopharmaceutical company focused on the discovery and development of novel, small molecule drug candidates for the treatment of patients suffering from fibrotic or inflammatory diseases that have a high unmet medical need. Liminal BioSciences operates on an integrated basis from our talent hubs in Laval, Quebec, Canada, and Cambridge, UK. Our common shares are listed for trading on the Nasdaq Global Market.


NDAQ:LMNL - Post by User

Bullboard Posts
Comment by francois21on Dec 12, 2014 1:35pm
440 Views
Post# 23224734

RE:RE:RE:RE:RE:RE:RE:RE:Réponse de Fred - Précisions sur les jalons de fin d'année

RE:RE:RE:RE:RE:RE:RE:RE:Réponse de Fred - Précisions sur les jalons de fin d'annéeOf ourse, there's things he can't tell! Reading between the lines, is that the term sheet on what they agreed was accepted by both parties. Now, the lawyers paper work might be a problem. Sometime, the way the contract is wrote doesn't reflect the term sheet. I know, it's delays again, but take 3-4 weeks more to make the deal, but make it right. Whatever won't be delivered in Q4, will be in the next Q1. If for some people it represent a problem, it's not one for me, neither for the analysts that do coverage.
Bullboard Posts